Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Neumora shuffles leadership ahead of IND—Chutes & Ladders

21 August 2026 · By · Wire by Fusion42

Published

21 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 22 August 2026 · Fusion42 review

Neumora Therapeutics has appointed Joshua Pinto as CEO and Doron Sagman as chief medical officer amid plans to submit an IND and start a phase 1 study for an obesity drug, alongside data readouts for Alzheimer’s and schizophrenia programs.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must engage with Neumora's changing leadership to align partnerships as they advance into clinical studies. Their upcoming phase 1 trial opens a timely window for neuro and obesity drug innovators to position themselves alongside this momentum.

◆ Coverage

1 source · 21 Aug 2026

◆ Related on Wire

◆ Topics

Biotechleadership-changeind-filingphase-1-trialneuropharmaobesity